패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Shattuck Labs, Inc. 4 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Yigal Nochomovitz	Citigroup Inc
Joseph Pantginis	H.C. Wainwright & Co.
Gil Blum	Needham & Company

Shattuck Labs 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Recent updates

Consensus revenue estimates increase by 11%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Consensus revenue estimates decrease by 19%, EPS upgraded

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Price target decreased by 27% to US$8.00

Shattuck Labs, Inc. Announces Strategic Pipeline Prioritization to Include the Discontinuation of Its Clinical Program, SL-172154

Consensus revenue estimates increase by 23%

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Co-Founder recently bought US$50k worth of stock

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Price target decreased by 7.9% to US$14.50

Shattuck Labs, Inc. Announces Committee Appointments

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 159%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Financial Officer recently sold US$250k worth of stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

New minor risk - Shareholder dilution

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

Price target increased by 21% to US$15.50

New major risk - Financial position

Consensus revenue estimates increase by 78%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 91%

New minor risk - Market cap size

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$2.03 loss

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus forecasts updated

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 264%

High number of new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021)

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$25.50

High number of new directors

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022

Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased to US$39.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc

Lead Independent Director recently bought US$56k worth of stock